# Pre-approval Single-patient Expanded Access for Talazoparib (PF-06944076)

> **NCT05650476** · — · AVAILABLE · sponsor: **Pfizer**

## Conditions studied

- Metastatic Castration-Resistant Prostate Cancer

## Interventions

- **DRUG:** Talazoparib

## Key facts

- **NCT ID:** NCT05650476
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** AVAILABLE
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2025-06-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05650476

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05650476, "Pre-approval Single-patient Expanded Access for Talazoparib (PF-06944076)". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT05650476. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*